Akari Therapeutics presents RNA-splicing payload strategy at ADC Payload Summit
AKTX•Akari Therapeutics will present its RNA-splicing antibody-drug conjugate payload strategy at the 3rd Annual ADC Payload Summit in Boston, November 4-6, 2026. The presentation will cover preclinical findings for PH1, the payload underlying lead candidate AKTX-101.
1. Summit presentation
Akari Therapeutics oncology head Satyajit Mitra will present on November 6 at 3:00 p.m. ET, discussing mechanisms that combine cancer-cell killing with immune activation. The presentation will examine preclinical findings supporting PH1, the payload underlying the company’s TROP2-targeting antibody-drug conjugate candidate AKTX-101.
